HC Wainwright Lowers Curis (NASDAQ:CRIS) Price Target to $20.00

Curis (NASDAQ:CRIS) had its target price lowered by HC Wainwright from $26.00 to $20.00 in a research note issued to investors on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Curis Stock Performance

Shares of CRIS stock opened at $4.33 on Friday. Curis has a 1 year low of $4.00 and a 1 year high of $17.49. The firm has a market cap of $25.89 million, a price-to-earnings ratio of -0.53 and a beta of 3.35. The stock’s 50-day moving average is $5.24 and its two-hundred day moving average is $7.67.

Institutional Investors Weigh In On Curis

A number of institutional investors and hedge funds have recently bought and sold shares of CRIS. Point72 Asset Management L.P. lifted its stake in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after buying an additional 96,256 shares during the period. CM Management LLC grew its stake in Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after acquiring an additional 95,000 shares during the period. Focused Wealth Management Inc raised its holdings in Curis by 63.1% in the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 20,908 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Curis by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after purchasing an additional 10,097 shares during the period. Hedge funds and other institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.